IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Condition(s):Acute Myeloid LeukemiaLast Updated:October 6, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Acute Myeloid LeukemiaLast Updated:October 6, 2023Recruiting
Condition(s):Myelodysplastic SyndromesLast Updated:January 31, 2024Not yet recruiting
Condition(s):Leukemia, Myeloid, AcuteLast Updated:October 11, 2023Recruiting
Condition(s):Diffuse Large B Cell LymphomaLast Updated:December 23, 2022Recruiting
Condition(s):Previously Untreated Acute Myeloid LeukemiaLast Updated:February 21, 2024Recruiting
Condition(s):AML, AdultLast Updated:January 18, 2024Recruiting
Condition(s):Acute Leukemia of Ambiguous LineageLast Updated:July 19, 2023Recruiting
Condition(s):Thrombocytopenia, Isolated; Stem Cell Transplant ComplicationsLast Updated:November 18, 2021Not yet recruiting
Condition(s):Myelodysplastic Syndromes; Dendritic Cell; Hypomethylating Agents; ImmunotherapyLast Updated:August 11, 2021Recruiting
Condition(s):Relapsed/Refractory AMLLast Updated:May 6, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.